Official Title
Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study
Brief Summary

This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.

Unknown status
COVID19
SARS-CoV Infection
Transplantation Infection

Diagnostic Test: SARS-CoV-2 IgG

Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies

Eligibility Criteria

Inclusion Criteria:

- all patients who underwent solid organ or hematopoietic cell transplantation at UZ
Leuven and who give informed consent

Exclusion Criteria:

- age under 18 years

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 90 Years
Countries
Belgium
Locations

UZ Leuven
Leuven, Vlaams Brabant, Belgium

Investigator: Jef Verbeek, MD
Contact: +32 16 345845
jef.verbeek@uzleuven.be

Investigator: Jef Verbeek, MD

Contacts

Jef Verbeek, MD, PhD
+ 32 16 34 42 25
jef.verbeek@uzleuven.be

Natalie Van den Ende
+32 16 340749
natalie.vandenende@uzleuven.be

Jef Verbeek, MD, PhD, Principal Investigator
UZ Leuven

Universitaire Ziekenhuizen KU Leuven
NCT Number
Keywords
COVID19
SARS-CoV Infection
Transplantation
MeSH Terms
Infections
Communicable Diseases
COVID-19
Severe Acute Respiratory Syndrome